FDA Classifies Hereditary Cancer NGS Panels as Class II: What Labs Need to Know
Short answer: Yes. In a final order scheduled for Federal Register publication on October 6, 2026, FDA classified high throughput DNA sequencing systems for hereditary cancer predisposition assessment as Class II with special controls, under new 21 CFR 866.6095. The device type remains subject to 510(k) premarket notification, with defined validation, interpretation and labeling requirements.
What FDA actually did
The document is a final amendment and final order from FDA, Docket No. FDA-2026-N-10990, amending 21 CFR Part 866. It is titled "Medical Devices; Immunology and Microbiology Devices; Classification of the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System" and is Federal Register Doc. 2026-20443. It adds 21 CFR 866.6095, classifies the device type into Class II rather than the Class III that applies automatically to postamendments devices, and takes effect on publication.
The path here began with a De Novo request. FDA received the request from Invitae Corporation, for the Invitae Common Hereditary Cancers Panel, on March 29, 2021. The classification itself has been applicable since September 29, 2023, when FDA issued its order to the requester. The October 2026 notice codifies that classification in the regulations so the device type is publicly defined.
How FDA defines the device
Under the new regulation, a high throughput DNA sequencing system for hereditary cancer predisposition assessment is a qualitative in vitro diagnostic system intended for analysis of human DNA extracted from human specimens, to detect germline mutations in a panel of targeted cancer-related genes. It is intended to aid in hereditary cancer predisposition assessment by qualified health care professionals in accordance with professional guidelines.
The boundaries matter for lab positioning. The device is not intended for screening, prenatal testing, or as a stand-alone diagnostic test, and it is for prescription use only. Germline testing is in scope; somatic testing is not. A medical director reviewing a test menu should map each hereditary cancer offering against this definition before drawing conclusions about its regulatory category.
The special controls: validation requirements
The first special control is design verification and validation, and it is detailed. The submitter must document genomic coverage, listing all genes, variant types and target regions, summarizing each gene's clinical significance with references, identifying high-significance genes and describing any within-gene regions that cannot be reported. It must also specify specimen requirements, DNA extraction methods and DNA quality and quantity criteria.
Methodology documentation must cover every test step, including reagents, instruments, software, mutation-detection algorithms, quality metrics, calling thresholds, filters and failure criteria for runs, batches, specimens, invalid calls and no-calls. Software requires verification, validation, hazard analysis and risk assessment. Internal and external controls must be documented, as must failure probability from clinical samples, failure scenarios and mitigations.
The analytical and clinical performance section sets numeric floors. Accuracy is measured against Sanger sequencing or another FDA-accepted orthogonal method, with positive and negative percent agreement and 95% confidence intervals. FDA calls for a minimum of 120 variant-positive specimens for BRCA1 and BRCA2 and at least 40 per other high-significance gene.
Accuracy thresholds are at least 99.0% for substitutions, insertions and deletions, and copy number variant positive agreement, and at least 99.9% for copy number variant negative agreement. Precision studies must span instruments, operators, days, reagent lots and sites, with point estimates above 99.0%. Studies also address input range, interference, stability, cross-reactivity, carryover and contamination, and specimen-type comparisons.
Variant interpretation is part of the device
FDA treats interpretation as part of the system, not an afterthought. The special controls require documented rules and criteria for linking mutations to hereditary disease and for classifying variants from pathogenic through benign. They also require documented interpretation protocols, including staff training, accuracy monitoring and discordance resolution, along with the evidence basis, data security and nomenclature.
Annotation algorithms must show they perform well, for example through concordance with external classifications, and the submitter must describe how new evidence is incorporated. For labs already managing reclassification workflows, see our guide on VUS reclassification and recontact responsibilities.
Labeling requirements
The second special control is labeling under 21 CFR 809.10. Labeling must state the intended use, including specimen type, validated mutation types and the hereditary cancer predisposition assessment statement, and must name the testing facility or facilities. It must summarize the device description and performance characteristics, explain how the test works and how to interpret results, and identify the databases used for annotation.
Required limiting statements include that the test is not stand-alone diagnostic, not for prenatal or screening use, and germline only. Labeling must also address the intended test population, the inability to predict an individual's cancer risk, interpretation in clinical context, and that a negative result does not rule out risk. It must note effects of ethnicity, challenging genomic contexts, coverage gaps and conditions that cause test failure. For variants of uncertain significance, labeling must state that clinical significance has not been demonstrated, and for variants with evidence of clinical significance it must give references for the level of evidence.
The risks FDA identified
FDA identified three risks to health: false positives, false negatives or failure to provide a result; incorrect interpretation of variants by the laboratory; and incorrect interpretation of test results by the healthcare provider. The same mitigations apply to each, namely the validation and interpretation requirements and the labeling requirements. The practical read for a lab director is that FDA frames lab-side variant classification and clinician-side result use as device risks, not just analytical performance.
What this means for laboratories
The order states that premarket notification under section 510(k) is required for this device type and that FDA has not exempted it under section 510(m). The document we reviewed does not state a comment deadline. It also describes requirements for the device type rather than addressing how they apply to any individual laboratory's own tests, so labs should confirm applicability with regulatory counsel. For the broader regulatory picture, see our overview of FDA LDT rule status in 2026.
Even where a lab never files a submission, the special controls are a useful benchmark. They give directors a concrete reference for validation study design, sample-size planning for BRCA1 and BRCA2, documentation of calling thresholds and failure criteria, and test-report labeling language. Compare them with your current validation package, and with payer expectations described in our summary of NCCN hereditary cancer testing guidelines and the MolDX inherited cancer syndromes LCD and billing article.
Operations and revenue cycle teams should note one practical point: documentation of intended use, specimen requirements and interpretation methodology is now defined at the federal level for this device type. Aligning order requisitions, report templates and medical-necessity documentation with the same language can reduce inconsistencies that surface during payer review. Platforms such as ScreenMyGene help labs and ordering clinicians keep that documentation consistent.
Frequently asked questions
Does this make every hereditary cancer panel an FDA-cleared test?
No. The order classifies the device type as Class II and keeps it subject to 510(k). It creates the regulatory category and special controls. It does not itself clear any individual test, and the document does not address how it applies to any specific laboratory's own test.
Which tests fall inside the definition?
The definition covers qualitative in vitro diagnostic systems that use high throughput DNA sequencing on human DNA to detect germline mutations in targeted cancer-related genes, to aid hereditary cancer predisposition assessment. Screening, prenatal use and stand-alone diagnosis are excluded, and prescription use only applies.
What are the key numeric validation thresholds?
Accuracy studies need at least 120 variant-positive specimens for BRCA1 and BRCA2 and 40 per other high-significance gene. Required agreement is at least 99.0% for substitutions, indels and CNV positive agreement, 99.9% for CNV negative agreement, and precision above 99.0%.
Why does FDA focus on variant interpretation?
FDA lists incorrect variant interpretation by the laboratory as one of three identified risks to health. The special controls therefore require documented classification criteria, staff training, accuracy monitoring, discordance resolution, evidence sources and a process for incorporating new evidence.
When does the classification take effect?
The final order takes effect on publication, scheduled for October 6, 2026. The classification itself has been applicable since September 29, 2023, when FDA issued the order to the requester. No comment deadline is stated in the document.
This article is for educational purposes only and is B2B decision support for laboratories and clinical teams. It is not legal, regulatory, billing or medical advice. Confirm requirements against the primary sources and with qualified counsel.
Sources: FDA, Medical Devices; Immunology and Microbiology Devices; Classification of the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System, Federal Register Doc. 2026-20443, Docket FDA-2026-N-10990 (public-inspection.federalregister.gov/2026-20443.pdf).